Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
2.600
-0.030 (-1.14%)
At close: Apr 1, 2025, 4:00 PM
2.500
-0.100 (-3.85%)
After-hours: Apr 1, 2025, 4:16 PM EDT

Revelation Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
4.434.515.495.041.23
Research & Development
3.554.155.386.912.56
Operating Expenses
7.988.6610.8611.953.8
Operating Income
-7.98-8.66-10.86-11.95-3.8
Other Non Operating Income (Expenses)
-7.068.540.03-0.040
Pretax Income
-15.04-0.12-10.83-11.99-3.8
Net Income
-15.04-0.12-10.83-11.99-3.8
Net Income to Common
-15.04-0.12-10.83-11.99-3.8
Shares Outstanding (Basic)
00---
Shares Outstanding (Diluted)
00---
Shares Change (YoY)
1103.92%----
EPS (Basic)
-87.68-8.44---
EPS (Diluted)
-87.68-8.44---
Free Cash Flow
-18.34-7.29-11.22-11.22-2.13
Free Cash Flow Per Share
-106.94-511.46---
EBITDA
-7.95-8.63-10.84-11.93-
D&A For EBITDA
0.030.030.030.02-
EBIT
-7.98-8.66-10.86-11.95-3.8
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q